A detailed history of Bellevue Group Ag transactions in Merus N.V. stock. As of the latest transaction made, Bellevue Group Ag holds 9,800 shares of MRUS stock, worth $462,462. This represents 0.01% of its overall portfolio holdings.

Number of Shares
9,800
Previous 9,800 -0.0%
Holding current value
$462,462
Previous $441,000 31.29%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$28.03 - $51.82 $361,587 - $668,478
-12,900 Reduced 56.83%
9,800 $441,000
Q4 2023

Feb 14, 2024

SELL
$20.06 - $28.66 $437,308 - $624,788
-21,800 Reduced 48.99%
22,700 $624,000
Q2 2023

Aug 14, 2023

SELL
$18.33 - $27.18 $21,995 - $32,616
-1,200 Reduced 2.63%
44,500 $1.17 Million
Q4 2022

Feb 14, 2023

BUY
$12.8 - $23.66 $259,840 - $480,298
20,300 Added 79.92%
45,700 $706,000
Q3 2022

Nov 14, 2022

BUY
$18.64 - $28.93 $473,456 - $734,822
25,400 New
25,400 $509,000

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.16B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.